Inventiva (NASDAQ:IVA) Shares Down 4.9% – Should You Sell?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) were down 4.9% on Monday . The stock traded as low as $3.62 and last traded at $3.5950. Approximately 70,300 shares changed hands during trading, a decline of 90% from the average session volume of 717,108 shares. The stock had previously closed at $3.78.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on IVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Guggenheim boosted their price objective on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Cantor Fitzgerald initiated coverage on Inventiva in a research note on Friday, July 17th. They set an “overweight” rating on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $15.75.

Inventiva Stock Performance

The stock’s fifty day simple moving average is $4.49 and its two-hundred day simple moving average is $4.81.

Institutional Investors Weigh In On Inventiva

Several institutional investors and hedge funds have recently bought and sold shares of the business. NEXTBio Capital Management LP acquired a new position in Inventiva in the fourth quarter valued at approximately $6,039,000. Propel Bio Management LLC acquired a new stake in shares of Inventiva during the 4th quarter worth approximately $4,650,000. Eventide Asset Management LLC acquired a new stake in shares of Inventiva during the 4th quarter worth approximately $1,155,000. Seven Fleet Capital Management LP bought a new stake in shares of Inventiva in the 1st quarter worth approximately $1,111,000. Finally, Persistent Asset Partners Ltd acquired a new position in Inventiva during the 4th quarter valued at approximately $603,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.